

# Mechanisms for Nonrecurrent Genomic Rearrangements Associated with CMT1A or HNPP: Rare CNVs as a Cause for Missing Heritability

Feng Zhang,<sup>1,2</sup> Pavel Seeman,<sup>3</sup> Pengfei Liu,<sup>1</sup> Marian A.J. Weterman,<sup>4</sup> Claudia Gonzaga-Jauregui,<sup>1</sup> Charles F. Towne,<sup>5</sup> Sat Dev Batish,<sup>5</sup> Els De Vriendt,<sup>6</sup> Peter De Jonghe,<sup>6</sup> Bernd Rautenstrauss,<sup>7,8</sup> Klaus-Henning Krause,<sup>8</sup> Mehrdad Khajavi,<sup>1</sup> Jan Posadka,<sup>3</sup> Antoon Vandenberghe,<sup>9</sup> Francesc Palau,<sup>10</sup> Lionel Van Malderghe,<sup>11</sup> Frank Baas,<sup>4</sup> Vincent Timmerman,<sup>6</sup> and James R. Lupski<sup>1,12,13,\*</sup>

Genomic rearrangements involving the peripheral myelin protein gene (*PMP22*) in human chromosome 17p12 are associated with neuropathy: duplications cause Charcot-Marie-Tooth disease type 1A (CMT1A), whereas deletions lead to hereditary neuropathy with liability to pressure palsies (HNPP). Our previous studies showed that >99% of these rearrangements are recurrent and mediated by nonallelic homologous recombination (NAHR). Rare copy number variations (CNVs) generated by nonrecurrent rearrangements also exist in 17p12, but their underlying mechanisms are not well understood. We investigated 21 subjects with rare CNVs associated with CMT1A or HNPP by oligonucleotide-based comparative genomic hybridization microarrays and breakpoint sequence analyses, and we identified 17 unique CNVs, including two genomic deletions, ten genomic duplications, two complex rearrangements, and three small exonic deletions. Each of these CNVs includes either the entire *PMP22* gene, or exon(s) only, or ultraconserved potential regulatory sequences upstream of *PMP22*, further supporting the contention that *PMP22* is the critical gene mediating the neuropathy phenotypes associated with 17p12 rearrangements. Breakpoint sequence analysis reveals that, different from the predominant NAHR mechanism in recurrent rearrangement, various molecular mechanisms, including nonhomologous end joining, *Alu-Alu*-mediated recombination, and replication-based mechanisms (e.g., FoSTeS and/or MMBIR), can generate nonrecurrent 17p12 rearrangements associated with neuropathy. We document a multitude of ways in which gene function can be altered by CNVs. Given the characteristics, including small size, structural complexity, and location outside of coding regions, of selected rare CNVs, their identification remains a challenge for genome analysis. Rare CNVs may potentially represent an important portion of “missing heritability” for human diseases.

## Introduction

Genomic disorders are the pathologic conditions caused by rearrangements of the human genome.<sup>1–3</sup> The 17p12 rearrangement-associated neuropathy is among the earliest identified genomic disorders: 17p12 duplications can lead to Charcot-Marie-Tooth disease type 1A (CMT1A [MIM 118220]) whereas deletions can lead to hereditary neuropathy with liability to pressure palsies (HNPP [MIM 162500]).<sup>4–7</sup> The CMT1A neuropathy phenotype is caused by a gene dosage effect.<sup>8</sup>

Genomic rearrangements can be categorized into two major groups: recurrent and nonrecurrent rearrangements.<sup>9</sup> Nonallelic homologous recombination (NAHR) between paralogous sequence repeats is the predominant mechanism underlying recurrent rearrangements with clustered breakpoints, whereas various mechanisms or models are implicated in nonrecurrent rearrangements with variable breakpoints.<sup>2,9</sup> Notably, a previous study showed that the NAHR-mediated, recombination hot-

spot-associated, recurrent rearrangements are specific to meiosis, i.e., germline events.<sup>10</sup>


The recurrent 17p12 rearrangements associated with CMT1A or HNPP are generated by NAHR events between two low-copy repeats (LCRs), alternatively termed segmental duplications (SDs),<sup>11</sup> specifically involving paralogous distal and proximal CMT1A-REP copies as homologous recombination substrates (Figure 1).<sup>12–14</sup> The common region affected by recurrent 17p12 rearrangements is ~1.4 Mb in length (Figure 1), and copy number variation (CNV) of the *PMP22* (peripheral myelin protein 22 [MIM 601097]) gene that maps within this genomic interval is responsible for the CMT1A and HNPP neuropathy phenotypes. This contention is supported by the studies of both point mutations and altered gene dosage of *PMP22*.<sup>7,15–19</sup>

It has been shown that most (>99%) of the CMT1A- or HNPP-associated rearrangements in 17p12 are recurrent and mediated by NAHR.<sup>20</sup> However, the role of nonrecurrent 17p12 rearrangements in neuropathy, and

<sup>1</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; <sup>2</sup>State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai 200433, China; <sup>3</sup>Department of Child Neurology, DNA Laboratory, 2nd School of Medicine, Charles University Prague and University Hospital Motol, V Úvalu 84, 15006 Praha 5, Czech Republic; <sup>4</sup>Neurogenetics Lab, Academic Medical Center Amsterdam, 1105 AZ Amsterdam, The Netherlands; <sup>5</sup>Athena Diagnostics, Inc., Worcester, MA 01605, USA; <sup>6</sup>Department of Molecular Genetics, VIB and University of Antwerp, B-2610 Antwerpen, Belgium; <sup>7</sup>Medical Genetics Center, Bayerstrasse 3-5, 80335 Munich, Germany; <sup>8</sup>Friedrich-Baur-Institute of the Ludwig-Maximilians-University, Ziemssenstrasse 1, 80336 Munich, Germany; <sup>9</sup>Biomnis Inc., F-69357 Lyon, France; <sup>10</sup>Institut de Biomedicina, Consejo Superior de Investigaciones Científicas, and CIBER de Enfermedades Raras (CIBERER), Valencia 46010, Spain; <sup>11</sup>Centre de Génétique Humaine, Université de Liège, B-4000 Liège, Belgium; <sup>12</sup>Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; <sup>13</sup>Texas Children's Hospital, Houston, TX 77030, USA

\*Correspondence: jlupski@bcm.tmc.edu

DOI 10.1016/j.ajhg.2010.05.001. ©2010 by The American Society of Human Genetics. All rights reserved.



**Figure 1. Oligonucleotide aCGH Analysis of Simple Nonrecurrent Genomic Rearrangements of 17p12 Associated with CMT1A or HNPP**

Above, for reference, is a horizontal line showing the 1.4 Mb common CMT1A- or HNPP-associated rearrangement region and its flanking sequences on human chromosome 17 with cytogenetic bands depicted above and Megabase (Mb) genomic coordinates (NCBI build 36) below. Locations of the *PMP22* gene, the distal and proximal CMT1A-REPs, and LCR17pA are shown. The black horizontal bar shows the location and size of common recurrent 17p12 rearrangements (both deletion and duplication)

the rearrangement mechanism(s) for such nonrecurrent rearrangements, have not been extensively investigated and are therefore not well understood.

To study the underlying mechanism(s) for 17p12 rearrangements and the critical gene(s) for the neuropathy phenotypes, we investigated 21 subjects with either CMT1A or HNPP neuropathy that were shown by previous assays to have apparent rare CNVs of atypical size in 17p12. We examined these genomic rearrangements by high-density oligonucleotide-based array comparative genomic hybridization (aCGH) and breakpoint sequence analyses. Our observations suggest that various mechanisms, including nonhomologous end joining (NHEJ), *Alu-Alu*-mediated recombination, and the newly proposed replication-based mechanisms, are involved in the CMT1A- or HNPP-associated nonrecurrent rearrangements. Furthermore, the studies confirm that *PMP22*, by either altered dosage or dysregulation, is the major gene responsible for the neuropathy phenotypes of CMT1A and HNPP. These studies document the multitude of structural changes that can alter gene function. Our findings implicate rare CNV in both Mendelian traits and sporadic diseases as well as being potentially responsible for some fraction of the missing heritability of apparent complex traits.

## Subjects and Methods

### Subjects

Twenty-one nonrecurrent rearrangements of 17p12 associated with CMT1A or HNPP were studied and summarized together with another nine nonrecurrent 17p12 rearrangements that we recently published.<sup>20</sup> The subjects were initially screened by the following conventional assays:<sup>20–24</sup> multiplex ligation-dependent probe amplification (MLPA): A23, A26, A29, B1369; restriction fragment length polymorphism (RFLP) genotyping with probes showing the recombination hotspots: B70, B89, B273.1, B273.2; microsatellite genotyping and MLPA: C1292, C2405, C2934, C3011, C3078, C3159, C4316; and Southern blot and MLPA: SPR1, SPR2, SP54C, SP951, SD11, SD14. Samples from CMT1A or HNPP subjects were obtained with informed consent approved by the Institutional Review Board for Human Subject Research at Baylor College of Medicine and/or collaborative institutions. Anonymous genomic DNAs (A23, A26, and A29) were provided by Athena Diagnostics (Worcester, MA). The female control DNA (NA15510) was obtained from Coriell Cell Repositories.

associated with CMT1A or HNPP. To the left are laboratory identification numbers of the subjects with nonrecurrent 17p12 rearrangements. The green (loss), black (no change), and red (gain) dots show the relative intensities (deviation from the horizontal line of  $\log_2\text{Ratio} = \text{zero}$ ) and genomic locations of the oligonucleotide probes employed in our aCGH assay. The regions that lack unique probes correspond to the LCRs. The regions with copy number gains are indicated in red horizontal bars, and the losses are shown in green. Related subjects: deletions B273.1 and B273.2; duplications C3159 and C4316. The blue vertical lines indicate the location of the *PMP22* gene. The arrow indicates the copy number change caused by known polymorphism in the control DNA (NA15510).

### Oligonucleotide-Based aCGH Analysis

We designed high-density oligonucleotide-based microarrays for a comparative genomic hybridization assay to finely examine the location, size, genomic content, and breakpoint interval of the 17p12 rearrangements associated with CMT1A or HNPP. This array is based on the Agilent 8 × 15K format. Approximately 15,000 oligonucleotide probes were selected from the Agilent eArray system to interrogate the 1.4 Mb common CMT1A or HNPP rearrangement region and its 1 Mb flanking regions with a genome resolution of ~300 bp. In subject C3011 whose rearrangement extends outside the array coverage of the 8 × 15K array, another 4 × 44K custom-designed CGH array covering the short arm of the human chromosome 17 was employed.<sup>20</sup> Probes having sequences complementary to more than one genomic locus have been purged and only unique sequence probes were employed. After digestion with *AluI* and *RsaI*, the test DNAs were labeled with Cy5-dCTP and control DNA was labeled with Cy3-dCTP by means of the BioPrime Array CGH genomic labeling kit (Invitrogen Corporation, Carlsbad, CA). Purification of labeling products, array hybridization, washing, scanning, and data analysis were conducted by following the Agilent oligonucleotide aCGH protocol (version 5.0).

### Long-Range PCR Amplification

The oligonucleotide aCGH data were used to initially pinpoint approximate breakpoint positions in the genome. We next designed outward-facing primers for presumed tandem duplications and used inward-facing primers for deletions to amplify rearrangement breakpoint junction.<sup>25</sup> Different orientations and combinations of primers were also tested for breakpoint analyses considering the potential for complex rearrangements. Long-range PCR was conducted with *TaKaRa LA Taq* polymerase. A 50 µl PCR reaction was performed with 2.5 U *TaKaRa LA Taq* polymerase with 1 × PCR buffer, 0.4 mM dNTP, 10 pmol of each primer, 1 µl DMSO, and 200 ng DNA template. The PCR conditions were as follows: 98°C for 30 s, 32 cycles at 94°C for 1 min, 65°C for 20 s, and 68°C for 20 min, followed by 68°C for 10 min.

### Breakpoint Sequence Analysis

PCR products that potentially contained breakpoint junctions were submitted to SeqWright DNA Technology Services (Houston, TX) for sequencing by the Sanger dideoxy method. DNA sequences were analyzed by comparing to the human genome reference assembly (NCBI Build 36) with the BLAT tool from the UCSC Genome Browser.

## Results

Twenty-one subjects with CMT1A or HNPP were initially found to have rare CNVs of atypical size in 17p12 by microsatellite genotyping, MLPA, RFLP, and/or Southern blot. These conventional assays are both locus-specific and “low-resolution” genome analysis tools for assessing CNVs. We employed high-density oligonucleotide-based aCGH for copy number determination and long-range PCR amplification for breakpoint determination and subsequent sequence analysis in this study to comprehensively examine the “genomotype” (i.e., location, size, genomic content, and simple or complex type of genomic

rearrangement)<sup>26</sup> and breakpoint interval of the nonrecurrent 17p12 rearrangements associated with CMT1A or HNPP.


### Genomic Deletion Rearrangements Involving *PMP22*

Three simple genomic deletions, two of which are from related subjects, were identified in this study (Figure 1). The deletion rearrangement in subject A26 is 536 kb in length, and the proximal breakpoint maps within the *PMP22* gene. Therefore, only the 3' end portion of *PMP22*, including coding exons 4 and 5, was deleted. Some genome rearrangements can have microhomologies at breakpoints, i.e., one or more nucleotides shared between distal and proximal reference sequences at the rearrangement ends.<sup>9</sup> However, no microhomology was detected at the breakpoint sequence of A26 (Figure S1 available online). As expected, the remaining two deletions in related subjects B273.1 and B273.2 (father and daughter) are the same. The 17p12 deletion in the B273 family is ~320 kb, which includes the entire *PMP22* gene. We surmise that B273.1 transmitted the deletion to B273.2. Breakpoint interval amplification was not achieved and no breakpoint sequence is available for the deletion in the B273 family. Because the rearrangement breakpoints in subjects B273.1 and B273.2 are apparently located outside LCR regions, as evidenced by a transition from normal copy to a loss relative to the control (i.e., a deletion CNV; Figure 1), a LCR-associated failure of specific amplification can probably be excluded. However, aCGH provides neither orientation nor genome positional information of DNA segments in the investigated genomic rearrangements. Considering that our long-range PCR assay can amplify DNA segments up to 15–20 kb in size, we hypothesize that a large insertion at the deletion breakpoint, or other complex rearrangement that is not resolvable in the aCGH assay, were potential causes precluding our ability to capture the breakpoint by PCR amplification of the perceived breakpoint interval in B273.1 and B273.2.

### Genomic Duplication Rearrangements Involving *PMP22*

Eight unique genomic duplications, varying from ~400 to 1048 kb in length, were found to have increased copy number of the entire *PMP22* gene (Figure 1). Related subjects C3159 and C4316 are brothers. The aCGH analysis showed that the duplications in C3159 and C4316 were the same. Therefore, we hypothesized that this duplication was inherited from one of their parents. However, no parental DNA sample is available for further study of parental origin. Breakpoint sequence analysis showed that both distal and proximal breakpoints of this duplication map within *AluY* elements (Figure S1).

Interestingly, six out of the remaining seven 17p12 duplications (B70, B89, B1369, C2934, C3078, and SP54C) have proximal breakpoints in LCRs, i.e., LCR17pA or proximal CMT1A-REP (Figure 1),<sup>27</sup> whereas their distal breakpoints are in unique genomic regions. Therefore, it



**Figure 2. CMT1A-Associated 17p12 Duplications Exclusive of the *PMP22* Coding Region but Involving the Potential Upstream Regulatory Sequence**

(A) Two duplications (red bars) of the upstream region of *PMP22* were identified in subject SPR1 and related subjects SD11 and SD14. The SRO involves the *TEKT3* and *CDRT4* genes, whereas *PMP22* is intact and has normal copy number. Both the noncoding exons (1A and 1B) and coding exons (2 to 5) are shown. Three ultra CNSs associated with conserved human transcription factor binding sites were present in SRO.

(B) The information of CNS size, lod score, and transcription factor binding site was provided. Details are provided in Figures S2 and S3.

can be challenging to amplify the specific breakpoint intervals in these subjects because of the inability to uniquely identify a specific genomic location for a PCR assay. Long-range PCR amplification was achieved only in subject SP54C and the breakpoint sequencing data revealed a recombination event between two *AluSg* elements (Figure S1).

In subject SP951, sequence complexity was identified in breakpoint sequence analysis (Figure S1). A 23 bp fragment (TAAAATTATCTTTTAGTCATTAA) was inserted at the join point between the distal and proximal breakpoints. This insertion can be copied from the DNA template that is only a few nucleotides adjacent to the distal breakpoint. These findings suggest the potential involvement of the serial replication slippage (SRS) mechanism in generating the complex duplication in SP951.<sup>28,29</sup> Alternatively, the sequence complexity is also consistent with multiple NHEJ events. The enzymatic features of both replication slippage and NHEJ mechanisms underlying genomic rearrangements have been summarized by Lieber (2010).<sup>30</sup>

### Genomic Duplication Involving Only the Sequences Upstream of *PMP22*

In addition to the genomic rearrangements inclusive of *PMP22*, it was recently reported that a genomic duplication affecting only the upstream region of *PMP22* can also lead to CMT1A potentially by altering the *PMP22* gene expression.<sup>24</sup> Two previously reported subjects (SD11 and SD14) with this 186 kb duplication<sup>24</sup> were also studied by oligonucleotide-based aCGH in this study and the rare CNV was confirmed. This duplication CNV affects only the upstream sequence with one breakpoint mapping ~34 kb proximal to the *PMP22* gene (Figure 2).<sup>24</sup> A 1 bp microhomology was identified at the breakpoint (Figure S1).

The other CMT1A-associated duplication devoid of the *PMP22* coding region was newly identified in subject SPR1 to be 194 kb in length with one breakpoint only ~9 kb proximal to the *PMP22* gene (Figure 2). The breakpoint sequence analysis showed a 5 bp microhomology (TCTCT) at the junctions (Figure S1).

It has been hypothesized that the CMT1A-associated duplications exclusive of the *PMP22* coding region may affect a conserved region upstream of *PMP22* and potentially cause dysregulation of *PMP22* gene expression.<sup>24</sup> The above two different duplications share a 168 kb smallest region of overlap (SRO; chr17:15,143,663-15,311,619, NCBI build 36) with one end that is located only 34 kb proximal to the *PMP22* gene. Several highly conserved noncoding sequences (CNSs) are located within this duplication SRO interval (Figure 2; Figure S2). These observations support the potential involvement of altered dosage or CNV of the regulatory regions for *PMP22* in the CMT1A-associated duplications exclusive of *PMP22* coding sequences.

### Clinical Findings in *PMP22* Upstream Duplication CNVs

No differentiating clinical features were observed specific to the CMT subjects with *PMP22* upstream duplications. However, their clinical phenotypes, although variable between individuals, appear milder than those usually mediated by *PMP22* gene duplications.

As for the 186 kb *PMP22* upstream duplication previously identified in multiple unrelated families (including subjects SD11 and SD14 in this study), the phenotype is variable between and within affected families.<sup>24</sup> However, milder phenotypes than those in classic CMT1A caused by *PMP22* duplications were observed in most cases, including relatively late age of onset, normal to brisk

reflexes, and mildly reduced nerve conduction velocities (NCVs).<sup>24</sup>

A relatively mild phenotype was also observed in subject SPR1 that was newly identified in this study to have a 194 kb *PMP22* upstream duplication CNV. Motor NCVs of upper and lower extremities were mildly reduced (median nerve right 44.5 m/s, ulnar nerve right 44 m/s, peroneal nerve right 30 m/s).


### Complex Rearrangements Involving *PMP22*

In addition to the simple types (either duplication or deletion) of nonrecurrent 17p12 rearrangements, we also identified three subjects with CMT1A-associated complex genomic rearrangements involving the entire *PMP22* gene (Figure 3). Subjects C1292 and C2405 are related; C2405 is the sister of C1292's maternal grandfather. High-density aCGH analysis revealed a 1294 kb complex rearrangement in 17p12 with aCGH data showing a pattern consistent with deletion-normal-duplication wherein the entire *PMP22* gene was duplicated (Figure 3). Breakpoint sequence analysis showed an *AluY-AluY*-mediated recombination between the distal end of the deletion and the proximal end of the duplication, whereas a 22 bp insertion of unknown origin was identified at the breakpoint interval between the distal end of duplication and the proximal end of deletion (Figure S1).

The genomic rearrangement in subject C3011 is the largest one among the 17 unique CMT1A or HNPP rearrangements. The proximal end of the genomic rearrangement in C3011 extended outside the coverage of our 8 × 15K CGH microarray interrogating the 1.4 Mb common 17p12 rearrangement region and its flanking sequences (1 Mb on each side; Figure 3). Therefore, a 4 × 44K CGH array covering the entire short arm of the human chromosome 17 was used to re-examine the genomic rearrangement in C3011. Interestingly, two additional segments with copy number gains were identified. These observations indicated a complex rearrangement of ~3.4 Mb in C3011 (Figure 3). Amplification of potential breakpoint intervals was achieved only between the distal and proximal ends of the small duplication from 17.73 to 17.86 Mb on the human chromosome 17 (NCBI build 36) and a 23 bp insertion of unknown origin was identified at the breakpoints (Figure S1).

### Exonic Rearrangements Deleting One or Several Exons of *PMP22*

Three exonic deletions were identified by our high-density aCGH analysis. The 5 kb deletion in subject A23 and the 13 kb deletion in subject A29 affect the coding exons 2 and 3 of *PMP22*, whereas the 17 kb deletion in subject SPR2 involves only the *PMP22* exon 4 (Figure 4). Breakpoint sequence analysis showed microhomologies at the breakpoints of both subjects A23 (A) and A29 (TC). No microhomology was identified at the breakpoint of subject SPR2, but instead a 3 bp short sequence (CAT) that did



### Figure 3. Oligonucleotide aCGH Analysis Revealed Complex Genomic Rearrangements in 17p12


(A) Subjects C1292 and C2405 are related (C2405 is the sister of C1292's maternal grandfather). Two proposed FoSTeS events (FoSTeS × 2) consistent with this complex rearrangement were shown.

(B) In C3011, the 17p CGH array (4 × 44k format) revealed additional duplications in 17p11.2 that is not covered by the CMT1A array (8 × 15k format). Rearrangement abbreviations: nml, normal; dup, duplication. This complex rearrangement can be alternatively interpreted as duplication-normal-duplication-normal-duplication or duplication-normal-duplication that is accompanied by an inversion polymorphism mediated by NAHR between two inverted LCRs (distal and proximal SMS-REPs).

not match the reference human genome sequence was found at the breakpoint (Figure S1).

### Discussion

Genomic rearrangements of 17p12 previously identified by conventional molecular assays in 21 subjects with



**Figure 4. Oligonucleotide aCGH Analysis of Exonic Rearrangements of *PMP22***

The deleted regions are shadowed. Below, the locations of the *PMP22* gene and its coding exons (2 to 5) are shown. Exon 4 is deleted in subject SPR2. Both subjects A23 and A29 have deletions of exons 1–3.

CMT1A or HNPP were newly investigated by high-resolution genome analysis with an oligonucleotide-based aCGH assay and breakpoint sequence analysis. Together with another nine (seven unrelated) subjects with nonrecurrent 17p12 rearrangements that were recently reported,<sup>20</sup> we now summarize the observations of 24 unique rare CNVs of 17p12 in 30 subjects with neuropathy (Table 1). All 30 subjects were ascertained by virtue of a neuropathy phenotype. By these analyses we narrow the critical region for CMT1A and HNPP, study the breakpoint characteristics, and infer the rearrangement mechanisms. We also show a multitude of ways that CNVs at this locus can cause neuropathy, including genotypes that do not even include any *PMP22* coding exons, i.e., upstream duplication CNVs.

#### ***PMP22* Is Critical for the 17p12 Rearrangement-Associated Neuropathy Phenotypes**

In the 1.4 Mb common recurrent rearrangements associated with CMT1A or HNPP, the *PMP22* gene is the dosage-sensitive gene involved in conveying the neuropathy phenotype. All 24 unique nonrecurrent types of 17p12 rearrangements mediate neuropathy by affecting (1) the entire *PMP22* gene (i.e., gene dosage), (2) individual *PMP22* exon(s), or (3) ultraconserved noncoding sequences upstream of *PMP22* (Figures 1–4). The SRO of the *PMP22* upstream duplications potentially reflects the genomic regions important to the regulation of *PMP22* gene expression (Figure 2).

Half (12 CNVs, 50%) of the 24 rare CNVs in 17p12 did not perturb the coding sequence integrity, but instead altered the gene copy number by deletion (two related subjects, B273.1 and B273.2), duplication (10 unique duplication CNVs), or even triplication (two related

subjects, A2 and A9) of the entire coding region of *PMP22* (Figures 1 and 3; Table 1).

Ten (42%) out of 24 rare CNVs in 17p12 are partial deletions of *PMP22*, including subjects A23, A26, A29, and SPR2 in this study and subjects A10, A11, A12, A14, A15, and A21 in our previous study.<sup>20</sup> These deletions affect only portions of the *PMP22* gene, i.e., only one or several exons. These observations suggest that not only deletions of the entire *PMP22* gene and point mutations in *PMP22*, but partial *PMP22* deletions involving only one or a few exons can also potentially result in loss-of-function mutations and haploinsufficiency of the *PMP22* protein and cause neuropathy.

No partial duplication of *PMP22* has been identified in this study. The bias of prevalent deletion versus rare duplication for exonic *PMP22* rearrangements in the subjects with neuropathies can be potentially explained by the argument that a portion of exonic *PMP22* duplications could be benign as indicated by the fact that these duplications do not alter *PMP22* gene dosage by creating an additional complete copy of *PMP22*. Interestingly, a 25 kb duplication involving *PMP22* exons 4 and 5 has been reported in the African (Yoruba) population of HapMap.<sup>31</sup> However, some *PMP22* exonic duplications may be pathogenic mutations through exon shuffling, insertional translocation, or other molecular mechanisms.<sup>32,33</sup>

Interestingly, Weterman et al.<sup>24</sup> recently reported identical 186 kb duplications in 11 subjects from 6 seemingly unrelated Dutch families. This duplication proximal to but exclusive of the coding region of *PMP22* can also lead to the CMT1A phenotype that is usually associated with copy number gain of *PMP22*. It was suggested by the haplotype study of Weterman et al.<sup>24</sup> that the neuropathy subjects with the 186 kb duplication share an ancestral mutation. The breakpoint sequence analysis of this current study showed that LCRs as NAHR substrates were absent at the breakpoints of the 186 kb duplication; therefore, the possibility of recurrent duplication events mediated by NAHR can be excluded. The 186 kb duplications from unrelated families probably have a common ancestral origin rather than multiple independent occurrences.

In addition to this 186 kb duplication, another duplication involving the upstream region of *PMP22* was identified during this study in subject SPR1. This 194 kb duplication of SPR1 is located closer to *PMP22* than that found in subjects SD11 and SD14 (9 kb versus 34 kb). There are two protein coding genes located in the SRO of the above two duplications: *TEKT3* (MIM 612683) and *CDRT4* (Figure 2). *TEKT3* encodes a putative testicular microtubule-associated protein that is primarily expressed in male germ cells,<sup>34</sup> whereas no molecular function has been reported for *CDRT4*. Instead, both increased dosage<sup>4,8</sup> and point mutations of *PMP22*<sup>15,19</sup> have been previously reported to cause CMT1A. Therefore, the *PMP22* gene is the most likely gene responsible for the neuropathy phenotype in these two upstream duplications. The

**Table 1. Summary of Nonrecurrent 17p12 Rearrangements with Breakpoint Characteristics and Underlying Mechanisms in 30 Subjects with Neuropathy**

Subject	Rearrangement	Size (kb)	Breakpoint Characteristics			Mechanism
			Distal	Proximal	Microhomology	
<b>Complex Rearrangement</b>						
C3011	dup-nml-dup-nml-dup	~3400 <sup>a</sup>		<i>AluJo</i>	N.A.	RBM
				<i>Alu/L2</i>	N.A.	
			SMS-REP	SMS-REP	N.A.	
C1292, C2405	del-nml-dup	1294 <sup>a</sup>	<i>AluY</i>	<i>AluY</i>	27 bp	RBM
			L1		N.A.	
A2, <sup>b</sup> A9 <sup>b</sup>	dup-tri-dup-nml-dup	520 <sup>a</sup>	<i>Alu/L1</i>		N.A.	RBM
				<i>Alu/L1/L2</i>	N.A.	
			LCR17pA	LCR17pA	N.A.	
A15, <sup>b</sup> A15.2 <sup>b</sup>	del-nml-del-nml-dup	9 <sup>a</sup>		L1	AACA	RBM (FoSTeS × 3)
				L1	AACCT	
					AAG	
<b>Duplication</b>						
C3159, C4316	dup	1048	<i>AluY</i>	<i>AluY</i>	24 bp	<i>Alu-Alu/RBM</i>
B89	dup	~590		LCR17pA	N.A.	N.A.
B70 <sup>b</sup>	dup	~500		LCR17pA	N.A.	N.A.
C2934	dup	~500	<i>Alu/L1</i>	LCR17pA	N.A.	N.A.
SP951	dup	437	L1	L2	none	NHEJ/RBM
			L1	L2	TTTA	
SP54C	dup	412	<i>AluSg</i>	<i>AluSg/LCR17pA</i>	GTTTCACCAT	<i>Alu-Alu/RBM</i>
B1369	dup	~400		LCR17pA	N.A.	N.A.
C3078	dup	~400	<i>Alu/L1</i>	LCR17pA	N.A.	N.A.
SPR1	dup	194			TCTCT	NHEJ/RBM
SD11, SD14	dup	186		<i>AluSq/x</i>	A	NHEJ/RBM
<b>Deletion</b>						
A26	del	536			none	NHEJ
B273.1, B273.2	del	~320		<i>Alu/L1</i>	N.A.	N.A.
A10 <sup>b</sup>	del	17	<i>AluJo</i>		GATT	NHEJ/RBM
SPR2	del	17	<i>AluJo</i>		none	NHEJ
A29	del	13			TC	NHEJ/RBM
A21 <sup>b</sup>	del	12			C	NHEJ/RBM
A11 <sup>b</sup>	del	7			AC	NHEJ/RBM
A23	del	5			A	NHEJ/RBM
A12 <sup>b</sup>	del	<1			GACG	NHEJ/RBM
A14 <sup>b</sup>	del	<1			GC	NHEJ/RBM

Note: Related subjects are listed in the same line.

Abbreviations: del, deletion; nml, normal; dup, duplication, tri, triplication; NHEJ, nonhomologous end joining; RBM, replication-based mechanism; N.A., not available.

<sup>a</sup> The sizes of the entire genomic region involved in complex rearrangements are shown.

<sup>b</sup> These subjects have been previously published.<sup>20,21</sup> Subject A15 and her affected sister A15.2 have the same complex exonic *PMP22* deletion, and their healthy mother is mosaic (both germ line and somatic) for the identical rearrangement.<sup>20</sup> B70 is the patient of the LF26 family published by Palau et al.<sup>21</sup>

hypothesized dysregulation of *PMP22* is supported by the observations of three ultraconserved noncoding sequences comprising conserved transcription factor binding sites in the SRO (Figure 2; Figures S2 and S3).

These findings in this study and the previous report suggest that not only *PMP22* gene duplications but duplication of the adjacent genomic region upstream of the *PMP22* gene can also lead to CMT1A potentially through altering *PMP22* gene expression. Notably, in both of the cases reported by Weterman et al.<sup>24</sup> and the different sized one reported herein, the duplications of upstream regulatory sequences conveyed a less severe phenotype than did *PMP22* gene duplications. Our observations in the neuropathy-associated 17p12 rearrangements involving the coding region or upstream regulatory region of the *PMP22* gene further confirm that *PMP22* is the critical gene for CMT1A and HNPP. Interestingly, in another dosage-sensitive gene (*PLP1* [MIM 300401]), the gene duplication of which causes the central nervous system dysmyelinating disorder Pelizaeus-Merzbacher disease (PMD [MIM 312080]), the duplication of downstream genomic region adjacent to *PLP1* is also associated with phenotypic consequences.<sup>35</sup> Thus, CNV either upstream or downstream from a dosage-sensitive gene may perturb gene regulation, perhaps through altering chromatin structure, remodeling, or other position effects underlying long-range control of gene expression.<sup>36</sup>

### Complex Rearrangements in 17p12 and DNA Replication-Based Mechanisms

In addition to the simple types (e.g., deletion or duplication) of nonrecurrent rearrangements, complex rearrangements also exist and play an important role in genomic disorders;<sup>25,37</sup> for example, complex rearrangements in 17p11.2 account for 57% of the nonrecurrent rearrangements associated with Potocki-Lupski syndrome (PTLS [MIM 610883]).<sup>20</sup> In our current study, we also identified complexities in four subjects: C3011; two related cases, C1292 and C2405, based on the aCGH assay (Figure 3); and SP951, based on the breakpoint sequence analysis (Figure S1). Taking the previously identified complex 17p12 rearrangements (related subjects A2 and A9 and related individuals A15 and A15.2 from family HOU1109)<sup>20</sup> into account, a sum of at least 21% (5/24) was identified to be complex in the rare 17p12 rearrangements associated with neuropathy. For six unique aCGH-based simple rearrangements (6/24, 25%), we could not obtain breakpoints; therefore, potential complexities may not have been identified at the level of resolution afforded by aCGH.

Notably, these complex CNVs cannot readily be explained by a simple rearrangement event mediated by the long-established DNA recombination mechanisms, for example, NAHR or NHEJ.<sup>2,9,38</sup> To explain the observations of both complexity and microhomology at the breakpoints, we proposed a replication fork stalling and template switching (FoSTeS) mechanism involving

DNA replication errors in human subjects.<sup>25</sup> Studies from both human subjects and other model organisms including bacteria and yeast further delineate the molecular details and proposed microhomology-mediated break-induced replication (MMBIR).<sup>39</sup> The MMBIR mechanism proposes: (1) fork stalling by a collapsed replication fork; as the replication fork proceeds through a DNA single-stranded nick and generates a one-ended, double-stranded DNA, that must be processed distinctly from a two-ended, double-stranded break that is the usual substrate for double-stranded break repair, and (2) template switching, as part of a break-induced replication, resulting in microhomology at the “join point” reflecting the priming of DNA replication on the new “template switched” fork. DNA replication-based mechanisms (RBMs) include serial replication slippage (SRS),<sup>28,29</sup> FoSTeS, and/or MMBIR,<sup>20,25,39</sup> microhomology/microsatellite-induced replication,<sup>40</sup> and other similar models. The details of these mechanisms have been reviewed recently.<sup>41,42</sup>

Microhomology, as a hallmark of RBM, can be traced at the breakpoints of complex rearrangements. In the related subjects C1292 and C2405, a microhomology of 27 bp shared by two *AluY* elements was detected at one of their breakpoints (Table 1; Figure S1), which was alternatively consistent with *Alu-Alu*-mediated recombination<sup>43,44</sup> and/or RBMs,<sup>26,41</sup> though the feature of rearrangement complexity in C1292 and C2405 is more parsimonious with the latter. In subject SP951, sequence-based complexity was identified at breakpoints, i.e., a 23 bp fragment that can be copied from an adjacent DNA template and inserted at the breakpoint by SRS<sup>28,29</sup> or other RBMs (Figure S1). However, only one microhomology of TTTA was identified at the breakpoint of SP951 (Table 1; Figure S1), whereas two microhomologies were expected according to the SRS model. The potential involvement of more complex rearrangement events cannot be excluded; for example, multiple NHEJ processes might generate such an event.<sup>30,41,45</sup> Two NHEJ events having no microhomology at the first breakpoint and a microhomology of TTTA at the second breakpoint can potentially cause the sequence complexity in SP951 (Figure S1).

### Various Mechanisms Involved in Nonrecurrent Rearrangements of 17p12

Distinct from one predominant NAHR mechanism in recurrent rearrangements, various mechanisms have been implicated in nonrecurrent rearrangements: NHEJ, *Alu-Alu*-mediated recombination, and RBMs have been shown to be involved in the nonrecurrent rearrangements in 17p12.

In the NHEJ events, an “information scar” of cleavage or addition of several nucleotides from or to the ends of double-strand break can be left at breakpoints,<sup>9,38</sup> which are characteristic and can help distinguish the NHEJ-mediated rearrangements from the rearrangement products of other mechanisms. In this study, no



**Table 2. Prevalence of Repeat and Repetitive Sequences at Breakpoints of 24 Unique Nonrecurrent Rearrangements in 17p12**

Rearrangement Type	Number	No. (%) of Breakpoints in Repeat or Repetitive Sequences	
		Distal	Proximal
<b>(1) Nonrecurrent Rearrangements of 17p12</b>			
Deletion	2	0 (0%)	1 (50%)
Duplication	10	5 (50%)	<b>9 (90%)</b>
Complex	3	<b>3 (100%)</b>	<b>3 (100%)</b>
All	15	<b>8 (53%)</b>	<b>13 (87%)</b>
<b>(2) Exonic Rearrangement of PMP22</b>			
Deletion	8	2 (25%)	0 (0%)
Complex	1	0 (0%)	<b>1 (100%)</b>
All	9	2 (22%)	1 (11%)

The percentages >50% are shown in **bold**.

microhomology is identified at the breakpoints of subjects A26 and SPR2. Instead, a 3 bp mismatched sequence (CAT) was identified at the breakpoint of SPR2. These observations, consistent with the nucleotide addition or cleavage, suggest that the NHEJ mechanism generated the nonrecurrent rearrangements in these two subjects.

*Alu-Alu*-mediated recombination is another mechanism for nonrecurrent rearrangement.<sup>43,44</sup> Different from previously reported uncommon NHEJ events that join two *Alu* elements together and generate a longer fused breakpoint sequence,<sup>46</sup> *Alu-Alu*-mediated recombination can cause a recombinant *Alu* with microhomology shared by two repetitive *Alu* elements. In related subjects C3159 and C4316, the breakpoint interval was mediated between two *AluY* elements, wherein a 24 bp microhomology was shared (Figure S1). In subject SP54C, the breakpoints are mediated between two *AluSg* elements, which shared a 10 bp microhomology (Figure S1). These above two nonrecurrent rearrangements are apparently consistent with an *Alu-Alu*-mediated recombination mechanism. However, considering the microhomologies that were identified at breakpoints, the involvement of RBMs (e.g., DNA template switching for only one time in the FoSTeS event resulting in a deletion or a duplication)<sup>20</sup> cannot be excluded.

In five subjects (A23, A29, SPR1, SD11, and SD14) with nonrecurrent rearrangements, microhomologies of 1 to 5 bp were identified at breakpoints, which can alternatively be explained by either NHEJ or RBMs.

### Prevalence of Repeat and Repetitive Sequences at Breakpoints of Nonrecurrent 17p12 Rearrangements

Distinct from the location of recurrent rearrangement breakpoints clustering in LCRs,<sup>9</sup> no such restriction has been reported for the breakpoints of nonrecurrent rearrangements. However, the presence of both repeat

and repetitive sequences at breakpoint junctions and the proximity of complex LCRs to breakpoint grouping have been reported in nonrecurrent duplications of *MECP2*, *RAI1*, and many other loci.<sup>27,37,47</sup> Similarly, the prevalence of repeats (i.e., LCRs or SDs) and repetitive sequences (including long interspersed elements [LINEs] and short interspersed elements [SINEs]) was observed in the neuropathy-associated genomic rearrangements of this study, especially in the genomic duplications and complex rearrangements (Tables 1 and 2).

We identified 24 unique CNVs in the 30 neuropathy-associated nonrecurrent rearrangements summarized in this study, including 15 large genomic rearrangements of 17p12 and 9 exonic rearrangements of the *PMP22* gene. The statistics of the breakpoints located in repetitive or repeat sequences are shown in Table 2. Interestingly, the prevalence of SINEs (e.g., *Alu* families), LINEs (e.g., L1 and L2), and LCRs (also rich in SINEs and LINEs) was observed in the breakpoints of large genomic rearrangements of 17p12, especially those of genomic duplications (distal, 50%; proximal 90%) and at least one breakpoint of each complex rearrangement (both distal and proximal, 100%) (Table 2), which is much higher than the composition of ~34% for LINEs and SINEs in the human genome.<sup>48</sup> Notably, 7 (54%) out of these 10 genomic duplications and 3 complex rearrangements of 17p12 have proximal breakpoints in LCR17pA. This finding is consistent with evolutionary studies of the proximal 17p region in primates, suggesting that LCRs or SDs acted as the seeds of serial segmental duplication events and led to more complex genomic architecture in 17p.<sup>49,50</sup> This finding is also consistent with the observed breakpoint grouping of nonrecurrent rearrangements seen at other genomic disorder loci, such as *PLP1* and *MECP2*.<sup>25,37</sup>

These observations reflect the special genomic architecture prone to genome instability. Because the repetitive sequences have been found to be associated with double-strand breaks or stalled replication, subsequent DNA repair via NHEJ or restarting DNA replication by template switching can be involved and lead to genomic rearrangements.<sup>51–53</sup>

The prevalence of repeats or repetitive sequences is not obvious at the breakpoints of small exonic *PMP22* rearrangements (Table 2). This phenomenon is possibly due to the below-average content of SINEs and LINEs in the *PMP22* gene region (24% in *PMP22* versus genome-wide 34%).

### Missing Heritability

Although tremendous efforts have been expended to dissect the genetic factors underlying human diseases, the genetic code accounts for only <20% of the known disease-associated variations in the human genome.<sup>54</sup> The genetic variation observed is only as good as the method used to detect it. Many of the variants described to be small, complex, and/or exclusive of gene coding regions in the present study are challenging and may not

be detected by currently implemented clinical assays for the CMT1A duplication and HNPP deletion. Rare CNVs caused by genomic rearrangements can be one source of variation potentially responsible for the “missing heritability” of human diseases.

In our previous studies,<sup>26</sup> we introduced a new concept of genototype (different from the traditional genotype) to describe CNVs of genomic segments and the study of such variations or changes in the context of genomic disorder phenotypes to determine genototype-phenotype correlations as a way to unravel the genomic code. In this study, we also showed how genomic alterations, such as deletion, duplications, and complex rearrangements involving exons, noncoding upstream sequences, the entire *PMP22* gene, or together with the flanking genomic regions, can lead to the neuropathy phenotypes of CMT1A and HNPP. Our study of rare CNVs with different sizes and genomic content in 17p12 further dissected the heritability associated with the neuropathy phenotype that is usually manifested by the 1.4 Mb common CNV in 17p12. Genototype-phenotype correlations will be particularly relevant to the elucidation of the genomic code, especially in the instances where the CNV does not involve coding sequences, because coding sequences account for <2% of the human genome.<sup>48</sup>

In summary, our study documents that various mechanisms, including NHEJ, *Alu-Alu*-mediated recombination, and RBMs (e.g., SRS, FoSTeS, and/or MMBIR), are implicated in the nonrecurrent 17p12 rearrangements associated with neuropathy phenotypes. We also further document that rare CNVs, even those exclusive of coding sequences, can cause human diseases and suggest that CNVs that do not either involve genes or include coding sequences can nevertheless effect gene regulation. We speculate that CNVs involving both coding and noncoding sequences may be a type of variation responsible for some fraction of missing heritability.

### Supplemental Data

Supplemental Data include three figures and can be found with this article online at <http://www.cell.com/AJHG>.

### Acknowledgments

We thank all participating subjects and families for their kind cooperation in the study. We also thank Drs. E. Ehler, V. Farhanová, R. Mazanec, and J. Zvolská for sending patients to the CMT1A DNA diagnostics. This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS, NIH) grant R01NS058529 to J.R.L.; Texas Children's Hospital General Clinical Research Center (GCRC) grant M01RR00188; and Intellectual and Developmental Disabilities Research Centers (IDRC) grant P30HD024064. F.Z. is supported by Shanghai Pujiang Program and the Ministry of Education of China grant NCET-09-0322. P.S. is supported by Ministry of Health of Czech Republic grant IGA NS 10554-3. P.D.J. and V.T. are supported by a Methusalem grant of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), and the Interuniversity Attraction Poles

program (P6/43) of the Belgian Federal Science Policy Office (BEL-SPO). B.R. is supported by the BMBF grant 01ES0815. J.R.L. is a consultant for Athena Diagnostics, 23andMe, and Ion Torrent Systems Inc., and holds multiple US and European patents for DNA diagnostics. Furthermore, the Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular diagnostic testing (Medical Genetics Laboratories).

Received: March 13, 2010

Revised: April 28, 2010

Accepted: May 3, 2010

Published online: May 20, 2010

### Web Resources

The URLs for data presented herein are as follows:

Agilent Technologies eArray, <http://earray.chem.agilent.com/earray/>  
Coriell Cell Repositories, <http://ccr.coriell.org/>  
Database of Genomic Variants (DGV), <http://projects.tcag.ca/variation/>  
Medical Genetics Laboratories at Baylor College of Medicine, <http://www.bcm.edu/geneticlabs/>  
Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/>  
UCSC Genome Browser, <http://genome.ucsc.edu/cgi-bin/hgGateway>

### References

1. Lupski, J.R. (1998). Genomic disorders: Structural features of the genome can lead to DNA rearrangements and human disease traits. *Trends Genet.* *14*, 417–422.
2. Stankiewicz, P., and Lupski, J.R. (2002). Genome architecture, rearrangements and genomic disorders. *Trends Genet.* *18*, 74–82.
3. Lupski, J.R. (2009). Genomic disorders ten years on. *Genome Med.* *1*, 42.
4. Lupski, J.R., de Oca-Luna, R.M., Slangenaupt, S., Pentao, L., Guzzetta, V., Trask, B.J., Saucedo-Cardenas, O., Barker, D.F., Killian, J.M., Garcia, C.A., et al. (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. *Cell* *66*, 219–232.
5. Chance, P.F., Alderson, M.K., Leppig, K.A., Lensch, M.W., Matsunami, N., Smith, B., Swanson, P.D., Odelberg, S.J., Distche, C.M., and Bird, T.D. (1993). DNA deletion associated with hereditary neuropathy with liability to pressure palsies. *Cell* *72*, 143–151.
6. Raeymaekers, P., Timmerman, V., Nelis, E., De Jonghe, P., Hoogendijk, J.E., Baas, F., Barker, D.F., Martin, J.J., De Visser, M., Bolhuis, P.A., et al. (1991). Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). *Neuromuscul. Disord.* *1*, 93–97.
7. Lupski, J.R., and Chance, P.F. (2005). Hereditary motor and sensory neuropathies involving altered dosage or mutation of *PMP22*: The CMT1A duplication and HNPP deletion. In *Peripheral Neuropathy*, P.J. Dyck and P.K. Thomas, eds. (Philadelphia: Elsevier Science), pp. 1659–1680.
8. Lupski, J.R., Wise, C.A., Kuwano, A., Pentao, L., Parke, J.T., Glaze, D.G., Ledbetter, D.H., Greenberg, F., and Patel, P.I. (1992). Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. *Nat. Genet.* *1*, 29–33.

9. Gu, W., Zhang, F., and Lupski, J.R. (2008). Mechanisms for human genomic rearrangements. *PathoGenetics* 1, 4.
10. Turner, D.J., Miretti, M., Rajan, D., Fiegler, H., Carter, N.P., Blayney, M.L., Beck, S., and Hurler, M.E. (2008). Germline rates of *de novo* meiotic deletions and duplications causing several genomic disorders. *Nat. Genet.* 40, 90–95.
11. Bailey, J.A., Gu, Z., Clark, R.A., Reinert, K., Samonte, R.V., Schwartz, S., Adams, M.D., Myers, E.W., Li, P.W., and Eichler, E.E. (2002). Recent segmental duplications in the human genome. *Science* 297, 1003–1007.
12. Pentao, L., Wise, C.A., Chinault, A.C., Patel, P.I., and Lupski, J.R. (1992). Charcot-Marie-Tooth type 1A duplication appears to arise from recombination at repeat sequences flanking the 1.5 Mb monomer unit. *Nat. Genet.* 2, 292–300.
13. Reiter, L.T., Murakami, T., Koeuth, T., Gibbs, R.A., and Lupski, J.R. (1997). The human *COX10* gene is disrupted during homologous recombination between the 24 kb proximal and distal CMT1A-REPs. *Hum. Mol. Genet.* 6, 1595–1603.
14. Reiter, L.T., Hastings, P.J., Nelis, E., De Jonghe, P., Van Broeckhoven, C., and Lupski, J.R. (1998). Human meiotic recombination products revealed by sequencing a hotspot for homologous strand exchange in multiple HNPP deletion patients. *Am. J. Hum. Genet.* 62, 1023–1033.
15. Valentijn, L.J., Baas, F., Wolterman, R.A., Hoogendijk, J.E., van den Bosch, N.H., Zorn, I., Gabreels-Festen, A.W., de Visser, M., and Bolhuis, P.A. (1992). Identical point mutations of *PMP-22* in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. *Nat. Genet.* 2, 288–291.
16. Patel, P.I., Roa, B.B., Welcher, A.A., Schoener-Scott, R., Trask, B.J., Pentao, L., Snipes, G.J., Garcia, C.A., Francke, U., Shooter, E.M., et al. (1992). The gene for the peripheral myelin protein *PMP-22* is a candidate for Charcot-Marie-Tooth disease type 1A. *Nat. Genet.* 1, 159–165.
17. Timmerman, V., Nelis, E., Van Hul, W., Nieuwenhuijsen, B.W., Chen, K.L., Wang, S., Ben Othman, K., Cullen, B., Leach, R.J., Hanemann, C.O., et al. (1992). The peripheral myelin protein gene *PMP-22* is contained within the Charcot-Marie-Tooth disease type 1A duplication. *Nat. Genet.* 1, 171–175.
18. Valentijn, L.J., Bolhuis, P.A., Zorn, I., Hoogendijk, J.E., van den Bosch, N., Hensels, G.W., Stanton, V.P. Jr., Housman, D.E., Fischbeck, K.H., Ross, D.A., et al. (1992). The peripheral myelin gene *PMP-22/GAS-3* is duplicated in Charcot-Marie-Tooth disease type 1A. *Nat. Genet.* 1, 166–170.
19. Roa, B.B., Garcia, C.A., Suter, U., Kulpa, D.A., Wise, C.A., Mueller, J., Welcher, A.A., Snipes, G.J., Shooter, E.M., Patel, P.I., et al. (1993). Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the *PMP22* gene. *N. Engl. J. Med.* 329, 96–101.
20. Zhang, F., Khajavi, M., Connolly, A.M., Towne, C.F., Batish, S.D., and Lupski, J.R. (2009). The DNA replication FoSTeS/MM-BIR mechanism can generate human genomic, genic, and exonic complex rearrangements. *Nat. Genet.* 41, 849–853.
21. Palau, F., Lofgren, A., De Jonghe, P., Bort, S., Nelis, E., Sevilla, T., Martin, J.J., Vilchez, J., Prieto, F., and Van Broeckhoven, C. (1993). Origin of the *de novo* duplication in Charcot-Marie-Tooth disease type 1A: Unequal nonsister chromatid exchange during spermatogenesis. *Hum. Mol. Genet.* 2, 2031–2035.
22. Timmerman, V., Rautenstrauss, B., Reiter, L.T., Koeuth, T., Lofgren, A., Liehr, T., Nelis, E., Bathke, K.D., De Jonghe, P., Grehl, H., et al. (1997). Detection of the CMT1A/HNPP recombination hotspot in unrelated patients of European descent. *J. Med. Genet.* 34, 43–49.
23. Seeman, P., Mazanec, R., Zidar, J., Hrusakova, S., Ctvrtckova, M., and Rautenstrauss, B. (2000). Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP): reliable detection of the CMT1A duplication and HNPP deletion using 8 microsatellite markers in 2 multiplex PCRs. *Int. J. Mol. Med.* 6, 421–426.
24. Weterman, M.A., van Ruissen, F., de Wissel, M., Bordewijk, L., Samijn, J.P., van der Pol, W.L., Meggouh, F., and Baas, F. (2010). Copy number variation upstream of *PMP22* in Charcot-Marie-Tooth disease. *Eur. J. Hum. Genet.* 18, 421–428.
25. Lee, J.A., Carvalho, C.M., and Lupski, J.R. (2007). A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. *Cell* 131, 1235–1247.
26. Bi, W., Sapir, T., Shchelochkov, O.A., Zhang, F., Withers, M.A., Hunter, J.V., Levy, T., Shinder, V., Peiffer, D.A., Gunderson, K.L., et al. (2009). Increased *LIS1* expression affects human and mouse brain development. *Nat. Genet.* 41, 168–177.
27. Stankiewicz, P., Shaw, C.J., Dapper, J.D., Wakui, K., Shaffer, L.G., Withers, M., Elizondo, L., Park, S.S., and Lupski, J.R. (2003). Genome architecture catalyzes nonrecurrent chromosomal rearrangements. *Am. J. Hum. Genet.* 72, 1101–1116.
28. Chen, J.M., Chuzhanova, N., Stenson, P.D., Ferec, C., and Cooper, D.N. (2005). Meta-analysis of gross insertions causing human genetic disease: Novel mutational mechanisms and the role of replication slippage. *Hum. Mutat.* 25, 207–221.
29. Chen, J.M., Chuzhanova, N., Stenson, P.D., Ferec, C., and Cooper, D.N. (2005). Complex gene rearrangements caused by serial replication slippage. *Hum. Mutat.* 26, 125–134.
30. Lieber, M.R. (2010). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu. Rev. Biochem.* 10.1146/annurev.biochem.052308.093131.
31. Kidd, J.M., Cooper, G.M., Donahue, W.F., Hayden, H.S., Sampas, N., Graves, T., Hansen, N., Teague, B., Alkan, C., Antonacci, F., et al. (2008). Mapping and sequencing of structural variation from eight human genomes. *Nature* 453, 56–64.
32. Kang, S.H., Shaw, C., Ou, Z., Eng, P.A., Cooper, M.L., Pursley, A.N., Sahoo, T., Bacino, C.A., Chinault, A.C., Stankiewicz, P., et al. (2010). Insertional translocation detected using FISH confirmation of array-comparative genomic hybridization (aCGH) results. *Am. J. Med. Genet. A.* 152A, 1111–1126.
33. Stankiewicz, P., Pursley, A.N., and Cheung, S.W. (2010). Challenges in clinical interpretation of microduplications detected by array CGH analysis. *Am. J. Med. Genet. A.* 152A, 1089–1100.
34. Roy, A., Yan, W., Burns, K.H., and Matzuk, M.M. (2004). *Tektin3* encodes an evolutionarily conserved putative testicular microtubules-related protein expressed preferentially in male germ cells. *Mol. Reprod. Dev.* 67, 295–302.
35. Lee, J.A., Madrid, R.E., Sperle, K., Ritterson, C.M., Hobson, G.M., Garbern, J., Lupski, J.R., and Inoue, K. (2006). Spastic paraplegia type 2 associated with axonal neuropathy and apparent *PLP1* position effect. *Ann. Neurol.* 59, 398–403.
36. Kleinjan, D.A., and van Heyningen, V. (2005). Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am. J. Hum. Genet.* 76, 8–32.
37. Carvalho, C.M., Zhang, F., Liu, P., Patel, P., Sahoo, T., Bacino, C.A., Shaw, C., Peacock, S., Pursley, A., Tavyev, Y.J., et al.

- (2009). Complex rearrangements in patients with duplications of *MECP2* can occur by fork stalling and template switching. *Hum. Mol. Genet.* *18*, 2188–2203.
38. Lieber, M.R. (2008). The mechanism of human nonhomologous DNA end joining. *J. Biol. Chem.* *283*, 1–5.
  39. Hastings, P.J., Ira, G., and Lupski, J.R. (2009). A microhomology-mediated break-induced replication model for the origin of human copy number variation. *PLoS Genet.* *5*, e1000327.
  40. Payen, C., Koszul, R., Dujon, B., and Fischer, G. (2008). Segmental duplications arise from Pol32-dependent repair of broken forks through two alternative replication-based mechanisms. *PLoS Genet.* *4*, e1000175.
  41. Zhang, F., Carvalho, C.M., and Lupski, J.R. (2009). Complex human chromosomal and genomic rearrangements. *Trends Genet.* *25*, 298–307.
  42. Hastings, P.J., Lupski, J.R., Rosenberg, S.M., and Ira, G. (2009). Mechanisms of change in gene copy number. *Nat. Rev. Genet.* *10*, 551–564.
  43. Bailey, J.A., Liu, G., and Eichler, E.E. (2003). An *Alu* transposition model for the origin and expansion of human segmental duplications. *Am. J. Hum. Genet.* *73*, 823–834.
  44. Sen, S.K., Han, K., Wang, J., Lee, J., Wang, H., Callinan, P.A., Dyer, M., Cordaux, R., Liang, P., and Batzer, M.A. (2006). Human genomic deletions mediated by recombination between *Alu* elements. *Am. J. Hum. Genet.* *79*, 41–53.
  45. Gajecka, M., Gentles, A.J., Tsai, A., Chitayat, D., Mackay, K.L., Glotzbach, C.D., Lieber, M.R., and Shaffer, L.G. (2008). Unexpected complexity at breakpoint junctions in phenotypically normal individuals and mechanisms involved in generating balanced translocations t(1;22)(p36;q13). *Genome Res.* *18*, 1733–1742.
  46. Elliott, B., Richardson, C., and Jasin, M. (2005). Chromosomal translocation mechanisms at intronic *Alu* elements in mammalian cells. *Mol. Cell* *17*, 885–894.
  47. Vissers, L.E., Bhatt, S.S., Janssen, I.M., Xia, Z., Lalani, S.R., Pfundt, R., Derwinska, K., de Vries, B.B., Gilissen, C., Hoischen, A., et al. (2009). Rare pathogenic microdeletions and tandem duplications are microhomology-mediated and stimulated by local genomic architecture. *Hum. Mol. Genet.* *18*, 3579–3593.
  48. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and analysis of the human genome. *Nature* *409*, 860–921.
  49. Inoue, K., Dewar, K., Katsanis, N., Reiter, L.T., Lander, E.S., Devon, K.L., Wyman, D.W., Lupski, J.R., and Birren, B. (2001). The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. *Genome Res.* *11*, 1018–1033.
  50. Stankiewicz, P., Shaw, C.J., Withers, M., Inoue, K., and Lupski, J.R. (2004). Serial segmental duplications during primate evolution result in complex human genome architecture. *Genome Res.* *14*, 2209–2220.
  51. Wells, R.D. (2007). Non-B DNA conformations, mutagenesis and disease. *Trends Biochem. Sci.* *32*, 271–278.
  52. Argueso, J.L., Westmoreland, J., Mieczkowski, P.A., Gawel, M., Petes, T.D., and Resnick, M.A. (2008). Double-strand breaks associated with repetitive DNA can reshape the genome. *Proc. Natl. Acad. Sci. USA* *105*, 11845–11850.
  53. Voineagu, I., Narayanan, V., Lobachev, K.S., and Mirkin, S.M. (2008). Replication stalling at unstable inverted repeats: Interplay between DNA hairpins and fork stabilizing proteins. *Proc. Natl. Acad. Sci. USA* *105*, 9936–9941.
  54. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the missing heritability of complex diseases. *Nature* *461*, 747–753.